These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25066551)

  • 1. Independent data monitoring committees: preparing a path for the future.
    Hess CN; Roe MT; Gibson CM; Temple RJ; Pencina MJ; Zarin DA; Anstrom KJ; Alexander JH; Sherman RE; Fiedorek FT; Mahaffey KW; Lee KL; Chow SC; Armstrong PW; Califf RM
    Am Heart J; 2014 Aug; 168(2):135-41.e1. PubMed ID: 25066551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance and role of independent data monitoring committees (IDMCs) in oncology clinical trials.
    Schöffski P
    BMJ Open; 2021 Oct; 11(10):e047294. PubMed ID: 34697110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On independent data monitoring committees in oncology clinical trials.
    Wittes J; Schactman M
    Chin Clin Oncol; 2014 Sep; 3(3):40. PubMed ID: 25841466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility.
    Buhr KA; Downs M; Rhorer J; Bechhofer R; Wittes J
    Ther Innov Regul Sci; 2018 Jul; 52(4):459-468. PubMed ID: 29714543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsors.
    Bhattacharyya A; Gallo P; Crisp A; LaVange L; Molenberghs G; Pétavy F; Seltzer J
    Biom J; 2019 Sep; 61(5):1232-1241. PubMed ID: 30589102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A third trial oversight committee: Functions, benefits and issues.
    Lane JA; Gamble C; Cragg WJ; Tembo D; Sydes MR
    Clin Trials; 2020 Feb; 17(1):106-112. PubMed ID: 31665920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent data monitoring committees: an update and overview.
    Sartor O; Halabi S
    Urol Oncol; 2015 Mar; 33(3):143-8. PubMed ID: 25631301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the role and function of trial steering committees: results of an expert panel meeting.
    Harman NL; Conroy EJ; Lewis SC; Murray G; Norrie J; Sydes MR; Lane JA; Altman DG; Baigent C; Bliss JM; Campbell MK; Elbourne D; Evans S; Sandercock P; Gamble C
    Trials; 2015 Dec; 16():597. PubMed ID: 26715378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases.
    Filippatos GS; de Graeff P; Bax JJ; Borg JJ; Cleland JG; Dargie HJ; Flather M; Ford I; Friede T; Greenberg B; Henon-Goburdhun C; Holcomb R; Horst B; Lekakis J; Mueller-Velten G; Papavassiliou AG; Prasad K; Rosano GM; Severin T; Sherman W; Stough WG; Swedberg K; Tavazzi L; Tousoulis D; Vardas P; Ruschitzka F; Anker SD
    Eur J Heart Fail; 2017 Apr; 19(4):449-456. PubMed ID: 28271595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues in regulatory guidelines for data monitoring committees.
    DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
    Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
    Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
    J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.